TD-HF831016

Lupartumab(TD-HF831016) is a research-grade recombinant antibody targetingC4.4A. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Human

IgG1-lambda

Monoclonal

C4.4A, Matrigel-induced gene C4 protein, GPI-anchored metastasis-associated protein C4.4A homolog, MIG-C4, LYPD3, Ly6/PLAUR domain-containing protein 3

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

O95274

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

BAY1112623, BAY1129980, 1640971-88-5

Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.• LY6/PLAUR domain containing 3 (LYPD3) maintains melanoma cell stemness and mediates an immunosuppressive microenvironment., PMID:37924160• m6A-dependent mature miR-151-5p accelerates the malignant process of HNSCC by targeting LYPD3., PMID:39009906• LY6/PLAUR domain containing 3 has a role in the maintenance of colorectal cancer stem-like cells., PMID:28238780• CircCBFB-mediated miR-28-5p facilitates abdominal aortic aneurysm via LYPD3 and GRIA4., PMID:32151690

SEC-HPLC detection for Research Grade Lupartumab.　　|　Detects LYPD3 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Lupartumab.

For research use only. Not suitable for clinical or therapeutic use.